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ATPase activityAiming to optimize macrocyclic lathyrane-type diterpenes as effective Pgp modulators, the phytochem-
ical study of the methanolic extract of Euphorbia boetica aerial parts was carried out. Two new macrocy-
clic 6,17-epoxylathyrane-type diterpenes, named epoxyboetiranes A (1) and B (2), along with three
known analogues (3–5) were isolated. Epoxyboetirane A (1), a triacetate isolated in large amounts,
was hydrolyzed to give epoxylathyrol (6). In order to study the effect of the substitution pattern of the
macrocyclic scaffold on MDR reversal, 6 was acylated with aroyl, phenylacetyl, cinnamoyl and alkanoyl
chlorides/anhydrides, yielding eight new esters, epoxyboetiranes C–J (7–14). The ability of compounds
1–14 as P-glycoprotein (Pgp, ABCB1) modulators was evaluated through combination of transport and
chemosensitivity assays, using L5178Y mouse T lymphoma cell line transfected with the human MDR1
gene. In the transport assay, excepting 1, 3 and 6, the compounds, at non-cytotoxic concentrations, dis-
played strong MDR reversing activity in a dose-dependent mode, exhibiting all the new acyl derivatives
(7–14) a many fold increase in the activity when compared with 1. Apart from 11 and 12, all compounds
exhibited remarkable synergistic effects in combination with doxorubicin. An ATPase assay, using mem-
brane vesicles from mammalian cells overexpressing Pgp, was also performed with two representatives
of the modulators (4 and 5). The results suggest that both compounds compete with substrates for the
Pgp drug-binding sites.
 2014 Elsevier Ltd. All rights reserved.1. Introduction
The chemotherapeutic strategies for the successful treatment of
cancer are frequently hampered by the occurrence of multidrug
resistance (MDR). MDR is a complex and multifactorial phenome-
non resulting from several mechanisms, of which, one of the most
relevant is related with the overexpression of transmembrane pro-
teins of the superfamily of ATP-binding cassette (ABC) transport-
ers. Among these proteins, the ABCB1 efﬂux pump also known as
P-glycoprotein (Pgp), the multidrug resistance-associated protein
(MRP1) and the breast cancer resistance protein (BCRP), have been
considered of major importance in the MDR phenomenon, corre-
lating with cancer chemoresistance to several drugs.1,2 Pgp, the
most studied and best known human ABC transporter, is character-
ized by a large drug-binding pocket, being able to extrude a large
variety of endogenous substrates and drugs with different chemi-
cal structures and mechanisms of action.3,4Among the several approaches that have been proposed to over-
come MDR,5 the co-administration of Pgp reversal agents (also
known as modulators or inhibitors) together with the anticancer
drug is considered to be one of the most promising, and great
efforts have been made to discover effective modulators.6 Different
inhibition mechanisms for drug efﬂux have been proposed,
namely, the blockage of drug binding sites competitively, non-
competitively or allosterically, the inhibition of ATP hydrolysis
and the alteration of the physicochemical properties of the cellular
membrane.5 However, despite the fact that several compounds
have been assayed in controlled clinical trials, until date there
are no reversal agents clinically available, and the search for inhib-
itors of P-glycoprotein still remains a challenging task.
Euphorbia species are characterized by an unusual diversity of
chemical constituents, which include, among others, a wide range
of structurally unique jatrophane and lathyrane macrocyclic diter-
pene polyesters, which have revealed to be promising Pgp
modulators.7,8
Aiming to optimize macrocyclic diterpenes as MDR reversal
agents,9,10 hereinwe report the isolation of ﬁve lathyranediterpenes
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tica. Furthermore, compound 1, isolated in large amounts, was
hydrolyzed and the resulting parental polyalcohol (6) was subse-
quently acylated affording eight new derivatives (7–14). Com-
pounds 1–14 were evaluated for their ability as Pgp modulators,
through the rhodamine-123 exclusion assay. Their in vitro antipro-
liferative effects in combinationwith the anti-cancerdrugdoxorubi-
cin were also assessed. Furthermore, an ATPase assay was also
performed with diterpenes 4 and 5.
2. Results and discussion
2.1. Chemistry
The air-dried powdered aerial parts of Euphorbia boetica were
exhaustively extracted with MeOH. Repeated chromatographic
fractionation and further puriﬁcation by HPLC of the EtOAc soluble
part of the methanol extract, yielded two newmacrocyclic lathyra-
ne diterpenes (1 and 2) (Fig. 1). The known lathyranes 5a,15b-
diacetoxy-3b-propanoyloxy-6(17)-epoxylathyr-12E-en-14-one (3),
5a,15b-diacetoxy-3b-butanoyloxy-6(17)-epoxylathyr-12E-en-14-
one (4) and 5a,15b-diacetoxy-3b-benzoyloxy-6(17)-epoxylathyr-
12E-en-14-one (5)11 (Fig. 1; referred as epoxyboetiranes K–L) were
also isolated along with the tetracyclic triterpene cycloart-23-ene-
3b,25-diol (15) and the tigliane diterpene euphodendriane A (16)
(Supplementary data). The known compounds were identiﬁed by
comparison of their physical and spectroscopic data to those
reported in the literature.11–13
2.1.1. Structural characterization of isolated compounds
Compound 1, named epoxyboetirane A, was isolated as white
crystals of mp 217–218 C, ½a25D +220.0. Its molecular formula
was determined as C26H36O8 from the HRESIMS (m/z 499.23041
[M+Na]+, calcd 499.23024). The presence of ester carbonyl
(1734 cm1) and conjugated ketone groups (1671 cm1) was sug-
gested by the IR spectrum. The 1H NMR spectrum displayed typical
signals for two oxymethine protons (dH 5.44 t, J = 3.1 Hz; 6.19 d,
J = 9.2 Hz), one diastereotopic oxymethylene group (dH 2.29 br s;
2.46 d, J = 3.4 Hz), one oleﬁnic proton (dH 6.57, d, J = 11.4 Hz) and
one vinylic methyl group (dH 1.83, s). 13C NMR and DEPT spectra
showed resonances corresponding to four methyls, four methyl-
enes (one oxygenated at dC 55.4), seven methines (two oxygenated
at dC 80.3 and 65.2, and one oleﬁnic at dC 143.8), ﬁve quaternary
carbons (one oleﬁnic at dC 136.0, two oxygenated at dC 91.8 and
59.0, and one carbonyl group at dC 196.9) and additional signals
for three acetyl groups. The above mentioned data indicated a
6(17)-epoxylathyr-12E-en-14-one diterpenic scaffold for 1.11,14,15
Further structural details were obtained by two-dimensional
NMR experiments (COSY, HMQC, and HMBC), which coupled withO CH3
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Figure 1. Chemical structures of 6,17-epoxylathyrane diterpliterature data, allowed unambiguous assignment of all carbon sig-
nals as well as the location of the acetyl groups at C-3, C-5 and C-15
(Supplementary data). The relative stereochemistry of 1 was
deduced through the analysis of a NOESY spectrum, assuming a
trans-ring fusion and an a orientation for H-4 (Supplementary
data), and by comparison of the coupling constant values with
those reported in the literature for similar diterpenes whose abso-
lute stereochemistry was determined by X-ray analysis.11,16
Compound 2, named epoxyboetirane B, was isolated as a
white amorphous powder of ½a25D +198.0, and its HREIMS showed
a pseudomolecular ion at m/z 541.28827 [M+Na]+ (calcd
541.28797). All its spectroscopic data clearly resembled those found
for compound 1, suggesting that both share the same 6,17-epoxyla-
thyrane scaffold, having however a slightly different acylation pat-
tern. In fact, the most remarkable difference was the absence of an
acetyl group (dH 2.00) that was replaced by the presence of new sig-
nals corresponding to a 3-methylbutanoyl group (dH 2.16, d,
J = 6.8 Hz; 2.04, m; 0.98 and 0.97, d, J = 5.5 Hz; dC 172.3, 43.5, 25.2,
22.8 and 22.7). The location of the 3-methylbutanoate ester at C-3
was deduced by the observation of a 3JC–H correlation between the
carbonyl signal (dC 172.3) and the oxymethine proton at dH 5.48.
The structure of compound 2 was conﬁrmed by extensive 2D NMR
experiments. The stereochemistry of all tetrahedral centers was
found to be identical to those of 1.
2.1.2. Acylated derivatives of epoxylathyrol
Macrocyclic diterpenes are generally found as polyesters. In
order to study the effect of the acylation pattern on the activity
and obtain a higher homologous set of compounds, epoxyboetirane
A (1), isolated in large amounts, was hydrolyzed to give the diter-
penic polyalcohol epoxylathyrol (6). Taking advantage of the free
hydroxyl groups at C-3, C-5 and C-15 of epoxylathyrol (6), eight
new esters, epoxyboetiranes C–J (7–14) were prepared using aroyl,
phenylacetyl, cinnamoyl and alkanoyl chlorides/anhydrides as
acylating reagents (Scheme 1). The structure of compounds 7–14
were characterized by comparison of their spectroscopic data with
those of epoxylathyrol (6). Brieﬂy, IR absorptions conﬁrmed the
presence of ester carbonyl groups (1715 cm1), and except for
compounds 10 and 14 that are tri-acylated, an hydroxyl absorption
band (3445 cm1) was also observed. As expected, the NMR data
of ester derivatives are very similar to those of epoxylathyrol (6)
regarding the lathyrane scaffold. The most signiﬁcant differences
were observed for H-3 and H-5 that exhibited a signiﬁcant para-
magnetic effect thus suggesting the presence of ester functions at
these positions. Similarly, major differences were also observed
at C-3, C-5 and also C-15 for compounds 10 and 14. The predicted
acylation pattern was conﬁrmed by the existence of new signals at
dC 163.7–181.0 in the 13C NMR spectra, which correlate with H-3 or
H-5 protons in the HMBC spectrum.CH3
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CH2CH3
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CH2CH2CH3
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2.2.1. In vitro antiproliferative assay
The antiproliferative activity of compounds 1–14was evaluated
using the MTT assay in L5178Y mouse lymphoma cells (PAR cells)
and in human MDR1-gene transfected L5178Y mouse lymphoma
cells (MDR cells). The compounds have not exhibited signiﬁcant
intrinsic cytotoxicity (IC50 values ranging from 43.0 ± 13.1 lM to
123.0 ± 13.6 lM, MDR cells; 36.6 ± 10. 6 lM to 111.1 ± 31.0 lM,
PAR cells, Supplementary data).
2.2.2. Inhibition of rhodamine-123 efﬂux Pgp-mediated
Many studies have been carried out to deﬁne the structural fea-
tures of ABCB1 modulators that might account for enhancing the
reversing activity. Among them, the existence of one or two planar
aromatic rings is considered an important feature for Pgp modula-
tion.10 Our previous studieswith jolkinolD derivatives on the ability
of macrocyclic diterpenes to revert Pgp-mediated MDR corroborate
this structural feature.9 Therefore, in this work, using several aro-
matic acyl chlorides, six new analogues of epoxyboetirane A (1)
were prepared (7–12). Compounds 13 and 14 were also prepared
aiming to evaluate the inﬂuence of the number of carbon atoms of
the alkanoyl residues on the activity. Diterpenes 1–14were investi-
gated for their ability to modulate the transport activity of Pgp on
MDR1 gene-transfected mouse T-lymphoma cells, using a standardO CH3
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Scheme 1. Preparation of 6,17-epoxylathyrol derivatives (7–14). Reagents and condition
anhydride, Pyr, 60 C reﬂux, 7 h; (d) 4-methylbenzoyl chloride, Pyr, rt, 48 h; (e) 4-meth
chloride, Pyr, 60 C reﬂux, 24 h; and (h) phenylacetyl chloride, Pyr, rt, 24 h.functional assay thatmeasures rhodamine-123 accumulation. Fluo-
rescence activity ratio (FAR) values were used to evaluate the Pgp
modulating potential. Accordingly, compounds with FAR values
higher than 1 were considered to be active as Pgp modulators and
those with FAR values higher than 10were regarded as strongmod-
ulators.17 Verapamil (22 lM) was applied as positive control. The
compounds were ﬁrstly tested at 20 lM. According to FAR values
obtained at this concentration, the compounds were further
assayed at 2, 40 or 80 lM aiming to obtain some information about
dose-dependent effects. The results are summarized in Table 2.
When tested at 20 lM, compounds 4, 5, 7–10 and 12–14were found
to be strong modulators of Pgp efﬂux pump activity, exhibiting FAR
values that range from 22.9 to 83.7. At this concentration, epox-
yboetiranes L and M (4 and 5, FAR values of 74.3 and 80.6, respec-
tively; Fig. 2), and epoxyboetiranes H (12, FAR = 73.4) and J (14,
FAR = 83.7) exhibited the highest effects in a dose-dependent mode
and amany fold activity when compared to that of the positive con-
trol (Fig. 2). When comparing FAR values of the derivatives 7–14,
with that of 1, a triacetylated natural compound (FAR = 1.0, at
20 lM), a 7 to 83-fold increase of the activity was observed for all
the esters prepared (FAR = 7.4–83.7, at 20 lM).
Interestingly, compound 12 where benzoyl (C6H5CO–) moieties
at C-3 and C-5, found in compounds 7–10, were replaced with
phenylacetyl (C6H5CH2CO–) units, exhibited the highest FAR values
among the aromatic set (73.4, at 20 lM), suggesting that the extrab.
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s: (a) KOH/MeOH (10%), rt, 4 h; (b) 2-ethylhexanoyl chloride, Pyr, rt, 48 h; (c) butyric
oxybenzoyl chloride, Pyr, rt, 48 h; (f) benzoyl chloride, Pyr, rt, 40 h; (g) cinnamoyl
Table 2
Multidrug resistance reversing activities of compounds 1–14 on human MDR1 gene-
transfected mouse lymphoma cells
Compound Concd (lM) FARa
Epoxyboetirane A (1) 20 1.0
80 35.0
Epoxyboetirane B (2) 20 7.8
80 22.6
Epoxyboetirane K (3) 20 1.0
80 58.6
Epoxyboetirane L (4) 2 8.0
20 74.3
40 96.9
Epoxyboetirane M (5) 2 63.4
20 80.6
40 102.9
Epoxylathyrol (6) 20 1.5
80 14.8
Epoxyboetirane C (7) 2 3.3
20 26.5
Epoxyboetirane D (8) 2 3.0
20 23.3
Epoxyboetirane E (9) 2 2.0
20 22.9
Epoxyboetirane F (10) 2 1.7
20 35.2
Epoxyboetirane G (11) 2 3.7
20 7.4
Epoxyboetirane H (12) 2 3.9
20 73.4
40 80.8
Epoxyboetirane I (13) 2 5.6
20 33.2
Epoxyboetirane J (14) 2 1.5
20 83.7
40 98.0
a FAR (ﬂuorescence activity ratio) values were calculated by using the equation
given in Section 4. The histograms were evaluated regarding the mean ﬂuorescence
intensity, the standard deviation and the peak channel of 20,000 individual cells
belonging to the total and the gated populations (see Supplementary data for
representative examples). FAR value of verapamil (positive control) at 22 lM: 17.5.
Table 1
NMR spectroscopic data for compounds 1 and 2 (1H 400 MHz, 13C 100.61 MHz; d in
ppm, J in Hz)
Position Epoxyboetirane A (1) Epoxyboetirane B (2)
dH dC dH dC
1a 3.38 dd (14.3, 8.4) 47.9, CH2 3.38 dd (14.3, 8.3) 48.1, CH2
1b 1.50 m 1.47 m
2 2.11 m 37.6, CH 2.07 m 37.2, CH
3 5.44 t (3.1) 80.3, CH 5.48 t (3.0) 80.2, CH
4 1.86 dd (9.2, 3.4) 50.0, CH 1.89 dd (9.4, 3.3) 50.1, CH
5 6.19 d (9.2) 65.2, CH 6.18 d (8.9) 65.3, CH
6 59.0, C 59.0, C
7a 0.90 m 33.5, CH2 0.91 m 33.6, CH2
7b 2.12 m 2.10 m
8a 1.71 m 20.0, CH2 1.72 m 20.0, CH2
8b 2.11 m 2.10 m
9 1.06 m 34.8, CH 1.08 m 34.8, CH
10 25.6, C 25.7, C
11 1.48 m 29.0, CH 1.52 m 29.0, CH
12 6.57 d (11.4) 143.8, CH 6.58 d (11.4) 143.8, C
13 136.0, C 136.0, C
14 196.9, C 197.0, C
15 91.8, C 91.8, C
16 0.85 d (6.7) 14.0, CH3 0.88 d (6.7) 14.2, CH3
17a 2.29 br s 55.4, CH2 2.31 br s 55.5, CH2
17b 2.46 d (3.4) 2.47 d (3.4)
18 1.18 s 28.9, CH3 1.19 s 28.9, CH3
19 1.18 s 16.7, CH3 1.19 s 16.8, CH3
20 1.83 s 12.4, CH3 1.85 s 12.4, CH3
3-OR 170.3, C 172.3, C
2.00 s 21.0, CH3 2.16 d (6.8) 43.5, CH2
2.04 m 25.2, CH
0.98 d (5.5) 22.8, CH3
0.97 d (5.5) 22.7, CH3
5-OR 169.7, C 169.7, C
2.08 s 21.9, CH3 2.11 s 21.9, CH3
15-OR 170.6, C 170.6, C
2.06 s 20.8, CH3 2.07 s 21.1, CH3
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binding sites. Surprisingly, compound 14, with three butyryl moi-
eties instead of the acetyl groups found in epoxyboetirane A (1),
was the most active compound at 20 lM (FAR = 83.7). This differ-
ence in the activity of both compounds might be explained mainly
by the increase of logP value in compound 14 (3.1 and 5.5 for com-
pounds 1 and 14, respectively). Similarly, diterpene 13 (logP = 7.0),
where the acetyl moieties of 1were replaced with 2-ethylhexanoyl
residues, has shown strong activity at 20 lM (FAR = 33.2). This is in
accordance with the criterion of lipophilicity deﬁned by Wang
et al.,18 who demonstrated that a highly effective Pgp modulator
should possess a logP value of 2.92 or higher. These results corrob-
orate the importance of aromatic residues in the lathyrane scaffold
but they also are in agreement with the assumption that this struc-
tural feature is not essential for the activity.19
2.2.3. Drug combination assays
Since most of the studied compounds showed to be good Pgp
modulators, further experiments were performed using a combina-
tion chemotherapy model, in order to study the type of in vitro
interactions between the diterpenes 1–14 and the anticancer drug
doxorubicin on MDR1 mouse T-lymphoma cells. Several concen-
trations of the compounds and the antitumor drug were tested.
The extent of interactions between doxorubicin and the tested
compound was calculated and expressed using the combination
index (CI) values.20–22 As can be observed in Table 3, excepting
for epoxyboetiranes G (11) and H (12) that exhibited a moderate
antagonistic effect, all the remaining compounds showed a syner-
gistic interaction with doxorubicin and ﬁve of them, epoxyboetir-
anes A (1), L (4) M (5), C (7) and E (9), displayed strong
interactions (CI = 0.20–0.29). However, the strongest synergisticeffect was found for epoxyboetirane K (3) that exhibited a remark-
ably low CI value (0.05), even though it did not display a good Pgp
modulation activity, suggesting that other mechanisms might be
responsible for its activity. On the other hand, epoxyboetirane H
(12) was a strong modulator of the efﬂux pump activity
(FAR = 73.4 at 20 lM) but, as referred, exhibited a moderate antag-
onistic effect in the drug combination assay (CI = 1.38).
2.2.4. Effects on the ATPase activity
As it was observed on the rhodamine-123 exclusion assay, at
the lowest concentration tested (2 lM), epoxyboetiranes L (4)
and M (5) are among the most active within the set of compounds
having aliphatic or aromatic acyl groups, respectively. Therefore,
they were selected as representatives of both set of compounds
to further characterize the kind of interaction that epoxylathyra-
ne-type diterpenes establish with the Pgp. Since Pgp efﬂuxes sub-
strates through ATP hydrolysis as an energy source, the inﬂuence
of compounds 4 and 5 on ATPase activity was assessed using puri-
ﬁed insect membrane vesicles expressing high levels of human Pgp
through a colorimetric detection.23 This assay has two complemen-
tary tests: the activation and the inhibition assays. While in the
ﬁrst assay compounds can be ranked as stimulating or inhibiting
the baseline vanadate-sensitive ATPase activity, the second one,
which is performed in the presence of a known Pgp activator, is
primarily used to characterize efﬂux inhibitors (or slowly trans-
ported substrates) through the reduction of verapamil-stimulated
vanadate-sensitive ATPase activity by the tested compound. Epox-
yboetiranes L (4) and M (5) were screened at four concentrations
(2, 10, 50 and 100 lM). Verapamil (40 lM) and cyclosporin A
Figure 3. Effect of epoxyboetiranes L (4, A) and M (5, B) on Pgp ATPase activity.
Activation assay: to test the effect on the basal ATPase activity. Inhibition assay: to
test the effect on drug-stimulated ATPase activity, measured in the presence of
verapamil (40 lM). Results are expressed as the mean ± SD from experiments
performed in triplicate. The effects of compounds were presented as the relative
ATPase activity, in which, the verapamil-stimulated vanadate-sensitive ATPase
activity is taken as 100% and the baseline vanadate-sensitive ATPase activity as 0%.
Figure 2. Reversal of the MDR phenotype by epoxyboetiranes L (4, A) and M (5, B)
at 2 and 20 lM. MDR: chemoresistant cell by overexpression of Pgp; PAR: parental
chemosensitive cell.
Table 3
Evaluation of the interaction between compounds 1–14 and doxorubicin on human
MDR1 gene-transfected mouse lymphoma cells
Compounds CI ± SE for IC50a Interaction
Epoxyboetirane A (1) 0.24 ± 0.03 Strong synergy
Epoxyboetirane B (2) 0.43 ± 0.05 Synergy
Epoxyboetirane K (3) 0.05 ± 0.03 Very strong synergy
Epoxyboetirane L (4) 0.20 ± 0.02 Strong synergy
Epoxyboetirane M (5) 0.27 ± 0.02 Strong synergy
Epoxylathyrol (6) 0.66 ± 0.08 Synergy
Epoxyboetirane C (7) 0.29 ± 0.05 Strong synergy
Epoxyboetirane D (8) 0.36 ± 0.06 Synergy
Epoxyboetirane E (9) 0.24 ± 0.12 Strong synergy
Epoxyboetirane F (10) 0.79 ± 0.16 Synergy
Epoxyboetirane G (11) 1.40 ± 0.10 Moderate antagonism
Epoxyboetirane H (12) 1.38 ± 0.33 Moderate antagonism
Epoxyboetirane I (13) 0.46 ± 0.10 Synergy
Epoxyboetirane J (14) 0.33 ± 0.10 Synergy
a Combination index (CI) values listed in the table are the mean ± standard error
(SE) for an inhibitory concentration of 50% (IC50, lM). CI < 0.1: very strong syner-
gism; 0.1 < CI < 0.3: strong synergism; 0.3 < CI < 0.9: synergism; 0.9 < CI < 1.1:
nearly additive; 1.10 < CI < 1.45: moderate antagonism.20–22
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bition assays, respectively. The effects of these compounds were
presented as the relative ATPase activity, in which, the stimulated
vanadate-sensitive ATPase activity is taken as 100% and the base-
line vanadate-sensitive ATPase activity as 0% (Fig. 3).
From the analysis of the ATPase activation assay (Fig. 3, dark
grey bars), it is clear that both compounds 4 and 5 have a stimula-
tory effect on the baseline vanadate-sensitive ATPase activity,
meaning that they effectively interact with Pgp. Interestingly, the
inhibition assay (Fig. 3, light grey bars) indicates that compound
5 is a much more potent inhibitor of verapamil-stimulated vana-
date-sensitive ATPase activity than compound 4. However, and asboth compounds inhibit verapamil-stimulated ATPase activity,
these ﬁndings suggest that both diterpenes 4 and 5 compete with
substrates for the Pgp drug-binding sites. Nonetheless, the modu-
latory activity of compound 5 seems to be more pronounced prob-
ably due to the presence of the aromatic moiety at C-3. These
results are consistent with the Pgp modulation pattern observed
on the rhodamine-123 exclusion assay.
3. Conclusions
In summary, these results emphasize the importance of the
acylation pattern of macrocyclic lathyrane diterpenes as MDR
reversal agents, namely the presence of aromatic residues. Never-
theless, two of the most active compounds lack this structural fea-
ture providing evidence that it is not essential for the activity.
In order to optimize macrocyclic diterpenes as valuable leads
for the development of Pgp modulators in multidrug-resistant can-
cer cells, further structure–activity relationship studies are still
needed, together with a deeper comprehension of their mecha-
nisms of interaction with Pgp.
4. Experimental section
4.1. General experimental procedures
Pyridine of HPLC grade was dried with solid KOH followed by
distillation and stored with Linde 4A molecular sieves. All the other
reagents and solvents were obtained from commercial suppliers
and were used without further puriﬁcation. Melting points were
determined on a Köpfﬂer apparatus and are uncorrected. Optical
rotations were obtained using a Perkin Elmer 241 polarimeter,
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determined on a Shimadzu IRAfﬁnity-1 FTIR. NMR spectra was
recorded on a Brüker ARX-400 NMR spectrometer (1H 400 MHz;
13C 100.61 MHz), using CDCl3 as solvent. 1H and 13C chemical shifts
are expressed in d (ppm) referenced to the solvent used and the
proton coupling constants J in Hertz (Hz). Spectra were assigned
using appropriate COSY, DEPT, HMQC and HMBC sequences. Low
resolution mass spectrometry (ESI-MS) was performed on a triple
quadrupole (QT) Micromass Quattro Micro AP1 (Waters, Milford,
USA) spectrometer, with ion source set in a positive ionization
mode. High resolution mass spectra were recorded on a FTICR-
MS Apex Ultra (Brüker Daltonics) 7T instrument. Column chroma-
tography (CC) was carried out on silica gel (Merck 9385). TLC were
performed on precoated silica gel F254 plates (Merck 5554 and
5744) and visualized under UV light and by spraying with
H2SO4–HOAc–H2O (1:20:4) or H2SO4–H2O (1:1) followed by heat-
ing. HPLC was carried out on a Merck-Hitachi HPLC system with
UV detection, using the Merck LiChrospher 100 RP-18 (5 lm,
125  4 mm) and 100 RP-18 (10 lm, 250  10 mm) columns and
mixtures of MeOH–H2O as eluents. All tested compounds were
puriﬁed to P95% purity as determined by HPLC.
4.2. Plant material
Euphorbia boetica Boiss. (Euphorbiaceae) was collected at Alco-
chete, Portugal (June 2010), and identiﬁed by Dr. Teresa Vasconce-
los of Instituto Superior de Agronomia (ISA), University of Lisbon. A
voucher specimen (469/2010) has been deposited at the herbarium
of ISA.
4.3. Extraction and isolation
The air-dried aerial parts (12.4 kg) were exhaustively extracted
with MeOH (13  28 L) at room temperature. The pooled extracts
were evaporated under vacuum to give a residue of 2.5 kg that
was suspended in a MeOH–H2O solution (1:1) and extracted with
EtOAc (10  9 L). The resulting EtOAc extract was dried (Na2SO4)
and evaporated, yielding a residue of 1.1 kg that was chromato-
graphed over silica gel (3.5 kg) with mixtures of n-hexane–EtOAc
and EtOAc–MeOH of increasing polarity. According to TLC differ-
ences, ten crude fractions were obtained (A–J). Fraction F (45.8 g)
was chromatographed on a polyamide column with mixtures of
MeOH–H2O (3:2–4:1) as eluents. Fraction obtained with MeOH–
H2O (3:2, 22.2 g) was further fractionated by CC using mixtures
of n-hexane–EtOAc (0:1–1:0) affording 12 subfractions. Fraction
F1D and F1F were recrystallized from EtOAc–n-hexane to give 3
(476 mg) and 1 (998 mg), respectively. The mother-liquors of frac-
tion F1D (4.7 g) were subject to CC using mixtures of CH2Cl2–Me2CO
(1:0–0:1) yielding three subfractions (F1D3, F1D4 and F1D6).
Fraction F1D3 (291 mg) was recrystallized (EtOAc–n-hexane) to
give 4 (27 mg). The mother liquors (174 mg) were puriﬁed by HPLC
(MeOH–H2O 13:7; 4.0 ml/min) to obtain 3 (Rt 31 min; 44 mg) and
2 (Rt 70 min; 12 mg). Fractions with Rt 50 and 60 min were further
puriﬁed by prep. TLC (CH2Cl2–Me2CO, 40:1; 2) affording 4
(27 mg) and 5 (15 mg), respectively. Sub-fraction F1D4 and F1D6
were recrystallized from EtOAc–n-hexane to give 1 (292 mg) and
15 (40 mg). Fraction G (30.5 g) was chromatographed on a polyam-
ide column with mixtures of MeOH–H2O (3:2 and 4:1) as eluents.
Fraction obtained with MeOH–H2O (3:2, 19 g) was further fraction-
ated by CC with mixtures of n-hexane–EtOAc and EtOAc–MeOH
(1:0–0:1), giving six subfractions. Fraction G1B (n-hexane–EtOAc
6:4; 1.3 g) yielded the diterpenes 1 (5 mg) and 16 (25 mg).
4.3.1. Epoxyboetirane A; 3b,5a,15b-triacetoxy-6(17)-
epoxylathyr-12E-en-14-one (1)
White crystals (EtOAc–n-hexane); mp 217–218 C; ½a25D +220.0
(c 0.12, CHCl3); IR (KBr): mmax 3031, 1734, 1671, 1619, 1377, 1255,1026 cm1; 1H NMR and 13C NMR data, see Table 1; ESIMSm/z 499
[M+Na]+, 515 [M+K]+; HR-ESIMS m/z 499.23041 [M+Na]+ (calcd for
C26H36O8Na: 499.23041).
4.3.2. Epoxyboetirane B; 5a,15b-diacetoxy-3b-(3-methyl)
butanoyloxy-6(17)-epoxylathyr-12E-en-14-one (2)
Amorphous solid; ½a25D +198.0 (c 0.13, CHCl3); IR (KBr): mmax
3030, 1710, 1604, 1421, 1265, 1032, 895 cm1; 1H NMR and 13C
NMR data, see Table 1; ESIMS m/z 541 [M+Na]+, 557 [M+K]+; HR-
ESIMS: m/z 541.28827 [M+Na]+, (calcd for C29H42O8Na:
541.28797).
4.4. Hydrolysis of epoxyboetirane A
Compound 1 (370 mg) in MeOH/KOH (10%) was stirred for 4 h
at room temperature. The reaction was worked up by dilution with
water (11 ml) and extraction with EtOAc. After drying (Na2SO4)
and removal of the solvent, 260 mg (yield 96%) of epoxylathyrol
(6) was obtained as an amorphous white powder (Supplementary
data).
4.5. General preparation of epoxylathyrol derivatives
A solution of epoxylathyrol (6) in dry pyridine (1–2 ml) was
stirred for 5 min at room temperature before addition of the
appropriate acyl chloride or anhydride. The mixture was stirred
for 7–48 h, at room temperature (rt) or under reﬂux (60 C, N2
atmosphere). The reaction mixture was concentrated under
vacuum at 40 C and the obtained residue was puriﬁed by ﬂash
column chromatography, preparative TLC or HPLC.
4.5.1. Preparation of epoxyboetirane C, 3b,5a-di(4-methyl-
benzoyloxy)-15b-hydroxy-6(17)-epoxylathyr-12E-en-14-one (7)
Compound 7 was obtained from reaction of 6 (35 mg) with
100 ll of 4-methylbenzoyl chloride (Sigma–Aldrich Chemie GmbH,
Riedstrasse D-89555, Steinheim, Germany). The residue was puri-
ﬁed by CC (n-hexane–CH2Cl2, 3:4, and CH2Cl2–EtOAc, 9:1) and
prep. TLC (CH2Cl2–EtOAc, 9:1) to give 27 mg (yield 46%) of an
amorphous white powder. ½a25D +19.0 (c 0.15, CHCl3); IR (KBr) mmax
3471, 3084, 1710, 1653, 1635, 1265, 895, 741 cm1; ESIMSm/z 609
[M+Na]+, 625 [M+K]+; 1H NMR (400 MHz, CDCl3): d 0.92 (3H, d,
J = 6.7 Hz, H-16), 0.93 (6H, s, H-18/H-19), 1.25 (1H, m, H-9), 1.76
(2H, m, H-11/H-8b), 1.91 (1H, m, H-1b), 2.03 (1H, m, H-7b), 2.05
(3H, s, H-20), 2.12 (2H, m, H-7a/H-8a) 2.18 (1H, m, H-2), 2.43
(6H, s, 4-OCH3), 2.50 (1H, br s, H-17), 2.51 (1H, m, H-4), 3.47 (1H,
dd, J = 9.2, 14.0 Hz, H-1a), 3.21 (1H, br s, 15-OH), 5.08 (1H, br s,
H-3), 6.12 (1H, br s, H-5), 6.28 (1H, br s, H-12), 7.26 (4H, d,
J = 8.0 Hz, H-40/H-400/H-60/H-600), 7.98 (4H, br s, H-30/H-300/H-70/H-
700); 13C NMR (100 MHz, CDCl3): 12.8 (C-20), 15.4 (C-16), 16.3 (C-
19), 20.3 (C-8), 21.7 (C-80/C-800), 25.8 (C-10), 28.9 (C-18), 29.1 (C-
11), 33.6 (C-7), 35.4 (C-9), 37.8 (C-2), 48.5 (C-1), 50.9 (C-4), 55.6
(C-17), 59.2 (C-6), 66.3 (C-5), 79.7 (C-3), 89.3 (C-15), 127.1 (C-50/
C-500), 129.2 (C-40/C-400/C-60/C-600), 129.9 (C-30/C-300/C-70/C-700),
135.9 (C-13), 144.1 (C-12), 148.2 (C-20/C-200), 166.2 (C-10), 171.2
(C-100), 206.9 (C-14).
4.5.2. Preparation of epoxyboetirane D, 3b,5a-di(4-methoxy-
benzoyloxy)-15b-hydroxy-6(17)-epoxylathyr-12E-en-14-one (8)
Compound 8 was obtained from reaction of 6 (20 mg) with
300 ll of 4-methoxybenzoyl chloride (Sigma–Aldrich Chemie
GmbH, Riedstrasse D-89555, Steinheim, Germany). The residue
was puriﬁed by CC (n-hexane–CH2Cl2, 1:1 and CH2Cl2–EtOAc,
9:1) and prep. TLC (CH2Cl2–EtOAc, 9:1) affording 16 mg (yield
45%) of an amorphous white solid. ½a25D +13.0 (c 0.23, CHCl3); IR
(KBr) mmax 3446, 3069, 2988, 1712, 1633, 1265, 737 cm1; ESIMS
m/z 641 [M+Na]+, 657 [M+K]+; 1H NMR (400 MHz, CDCl3): d 0.96
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H-11), 1.24 (3H, d, J = 6.7 Hz, H-16), 1.41 (1H, m, H-8a), 1.56 (1H,
m, H-1b), 2.02 (1H, m, H-7b), 2.03 (3H, s, H-20), 2.04 (1H, m, H-
2), 2.10 (6H, s, H-18/H-19), 2.31 (1H, m, H-17b), 2.40 (1H, m, H-
17a), 2.42 (1H, m, H-4), 3.14 (1H, m, H-1a), 3.86 (6H, s, OCH3-50/
OCH3-500), 5.04 (1H, br s, H-3), 6.10 (1H, br s, H-5), 6.22 (1H, br s,
H-12), 6.94 (4H, d, J = 9.3 Hz, H-30/H-300/H-70/H-700), 8.06 (4H, br s,
H-40/H-400/H-60/H-600); 13C NMR (100 MHz, CDCl3): 12.8 (C-20),
14.2 (C-16/C-19), 20.3 (C-8), 28.8 (C-10), 30.9 (C-11), 33.6 (C-18),
34.9 (C-9), 35.9 (C-7), 37.8 (C-2), 48.5 (C-1), 52.4 (C-17/C-4), 55.5
(C-80/C-800), 60.4 (C-6), 67.4 (C-5), 74.5 (C-3), 89.1 (C-15), 113.7
(C-30/C-300/C-70/C-700), 122.1 (C-20/C-200), 131.8 (C-50/C-500), 132.0
(C-40/C-400/C-60/C-600), 136.0 (C-13), 148.5 (C-12), 163.7 (C-100),
166.4 (C-10), 207.1 (C-14).
4.5.3. Preparation of epoxyboetiranes E (9) and F (10)
Compounds 9 and 10 were obtained from reaction of 6 (20 mg)
with 263 ll (2.26 mmol) of benzoyl chloride (Merck KGaA, Darms-
tadt, Germany). The residue was puriﬁed by CC (n-hexane–CH2Cl2,
1:1 and CH2Cl2–EtOAc, 9:1) and prep. TLC (CH2Cl2–EtOAc, 9:1) to
give 7 mg of 9 (yield 21%) and 7 mg of 10 (yield 19%) as white
amorphous solids.
Epoxyboetirane E, 3b,5a-dibenzoyloxy-15b-hydroxy-6(17)-epoxyl-
athyr-12E-en-14-one (9): ½a25D +91.0 (c 0.18, CHCl3); IR (KBr) mmax
3482, 3079, 1710, 1653, 1636, 1265, 896, 739 cm1; ESIMS m/z
581 [M+Na]+, 597 [M+K]+; 1H NMR (400 MHz, CDCl3): d 0.96 (3H,
d, J = 6.0 Hz, H-16), 1.13 (6H, s, H-18/H-19), 1.35 (1H, m, H-8b),
1.41 (1H, m, H-11), 1.45 (1H, m, H-7b), 1.54 (1H, m, H-9), 1.77
(1H, m, H-1b), 1.87 (1H, m, H-8a), 1.95 (1H, m, H-7a), 2.06 (3H, s,
H-20), 2.18 (1H, m, H-2), 2.52 (1H, dd, J = 9.4, 14.7 Hz, H-4), 2.63
(1H, d, J = 3.5 Hz, H-17a), 2.96 (1H, br s, H-17b), 3.40 (1H, m, H-
1a), 3.88 (1H, s, 15-OH), 4.64 (1H, br s, H-3), 5.90 (1H, d,
J = 10.5 Hz, H-5), 6.02 (1H, d, J = 11 Hz, H-12), 7.48 (4H, m, H-40/
H-400/H-60/H-600), 7.61 (2H, m, H-50/H-500), 8.12 (4H, m, H-30/H-300/
H-70/H-700); 13C NMR (100 MHz, CDCl3): 14.1 (C-20), 15.4 (C-16),
15.8 (C-8), 16.6 (C-19), 24.9 (C-10), 26.3 (C-11), 28.7 (C-18), 29.0
(C-7), 33.8 (C-9), 37.0 (C-2), 47.9 (C-1), 50.4 (C-17), 51.5 (C-4),
53.5 (C-6), 71.8 (C-5), 73.8 (C-3), 85.2 (C-15), 128.5, 128.6 (C-40/
C-400/C-60/C-600), 129.1 (C-20), 129.3 (C-200), 130.2 (C-30/C-300), 130.1
(C70/C-700), 133.8 (C-50), 136.4 (C-13), 142.9 (C-12), 165.9 (C-100),
171.5 (C-10), 206.4 (C-14).
Epoxyboetirane F, 3b,5a,15b-tribenzoyloxy-6(17)-epoxylathyr-
12E-en-14-one (10): ½a25D +16.7 (c 0.30, CHCl3); IR (KBr) mmax
3054, 1710, 1636, 1608, 1265, 896, 739 cm1; ESIMS m/z 685
[M+Na]+, 701 [M+K]+; 1H NMR (400 MHz, CDCl3): d 0.86 (1H, m,
H-9), 1.10 (3H, m, H-16), 1.19 (3H, s, H-18/H-19), 1.32 (2H, m, H-
7b/H-8b), 1.55 (1H, dd, J = 7.1, 11.4 Hz, H-11), 1.85 (3H, m, H-1b/
H-7a/H-8a), 1.98 (3H, s, H-20), 2.11 (1H, d, J = 2.4 Hz, H-17b),
2.21 (1H, m, H-2), 2.44 (1H, br s, H-17a), 2.79 (1H, m, H-4), 3.80
(1H, dd, J = 9.2, 14.5 Hz, H-1a), 5.10 (1H, br s, H-3), 6.06 (1H, d,
J = 10.1 Hz, H-5), 6.19 (1H, d, J = 9.8 Hz, H-12), 7.39 (6H, m, H-40/
H-400/H-400 0/H-60/H-600/H-6000), 7.52 (3H, m, H-50/H-500/H-5000), 8.03
(6H, m, H-30/H-300/H-3000/H-70/H-700/H-7000); 13C NMR (100 MHz,
CDCl3): d 13.7 (C-20), 14.2 (C-16), 15.4 (C-19), 19.1 (C-8), 25.7
(C-10), 29.7 (C-11), 28.8 (C-18), 29.7 (C-7), 33.5 (C-9), 37.9 (C-2),
48.6 (C-1), 52.3 (C-17), 52.4 (C-4), 60.4 (C-6), 64.5 (C-5), 77.3 (C-
3), 91.3 (C-15) 128.4 (C-40/C-60), 128.52 (C-30/C-50/C-70), 129.3 (C-
500), 129.9 (C-400/C-4000/C-600/C-6000), 129.9 (C-20), 130.1 (C-5000), 130.2
(C-300/C-3000/C-700/C-7000) 133.2 (C-20), 133.3 (C-200), 133.6 (C-2000),
136.1 (C-13), 143.3 (C-12), 170.4 (C-10/C-100/C-1000), 196.8 (C-14).
4.5.4. Preparation of epoxyboetirane G, 3b-cinnamoyloxy-5a,
15b-dihydroxy-6(17)-epoxylathyr-12E-en-14-one (11)
Compound 11 was obtained from reaction of 6 (37 mg) with
16 mg of cinnamoyl chloride (Merck KGaA, Darmstadt, Germany).
The residue was puriﬁed by prep. TLC (CH2Cl2–EtOAc, 9:1) to give35 mg (yield 69%) of an amorphous white solid. ½a25D +101 (c 0.40,
CHCl3); IR (KBr) mmax 3445, 3054, 1709, 1670, 1605, 1265, 896,
739 cm1; ESIMS m/z 503 [M+Na]+, 519 [M+K]+; 1H NMR
(400 MHz, CDCl3): d 0.72 (1H, m, H-9), 1.09 (3H, d, J = 6.8 Hz, H-
16), 1.10 (3H, s, H-19), 1.15 (3H, s, H-18), 1.19 (1H, m, H-7b),
1.43 (1H, dd, J = 8.5, 11.0 Hz, H-11), 1.64 (1H, m, H-8b), 1.65 (1H,
dd, J = 9.9, 14.8 Hz, H-1b), 1.92 (1H, m, H-8a), 1.96 (1H, m, H-7a),
1.98 (3H, s, H-20), 2.15 (1H, m, H-2), 2.60 (1H, m, H-4), 2.62 (1H,
d, J = 2.1 Hz, H-17a), 2.65 (1H, d, J = 3.8 Hz, H-17b), 3.00 (1H, dd,
J = 9.5, 14.3 Hz, H-1a), 5.82 (1H, d, J = 9.7 Hz, H-12), 5.98 (1H, br
s, H-3), 6.45 (1H, d, J = 16 Hz, H-20), 6.68 (1H, d, J = 9.4 Hz, H-5),
7.40 (3H, m, H-60/H-70/H-80), 7.54 (2H, m, H-50/H-90), 7.77 (1H, d,
J = 16 Hz, H-30); 13C NMR (100 MHz, CDCl3): d 13.9 (C-20), 14.1
(C-16), 15.3 (C-19), 19.4 (C-8), 25.2 (C-10), 28.4 (C-11), 28.8 (C-
18), 31.5 (C-7), 34.7 (C-9), 38.3 (C-2), 44.3 (C-1), 49.7 (C-17), 53.5
(C-4), 59.5 (C-6), 72.3 (C-5), 79.0 (C-3), 87.7 (C-15), 117.4 (C-20),
128.3 (C-50e 90), 129.0 (C-60/C-80), 130.7 (C-70), 134.1 (C-40), 136.7
(C-13), 140.1 (C-12), 146.8 (C-30), 171.1 (C-10), 206.1 (C-14).
4.5.5. Preparation of epoxyboetirane H, 15b-hydroxy-3b,5a-
diphenylacetyl-6(17)-epoxylathyr-12E-en-14-one (12)
Compound 12 was obtained from reaction of 6 (25 mg) with
400 ll of phenylacetyl chloride (Merck KGaA, Darmstadt,
Germany). The residue was puriﬁed by CC (n-hexane–CH2Cl2,
1:1–0:1 and CH2Cl2–EtOAc, 9:1) and HPLC (MeOH–H2O, 7:3, 254 nm,
4 ml/min) to give 17 mg (yield 40%) of a yellow amorphous solid.
½a25D +35 (c 0.10, CHCl3); IR (KBr) mmax 3442, 3054, 1713, 1653,
1636, 1265, 896 cm1; ESIMS m/z 609 [M+Na]+, 625 [M+K]+; 1H
NMR (400 MHz, CDCl3): d 0.76 (1H, m, H-7b), 0.92 (3H, d,
J = 6.8 Hz, H-16), 1.03 (1H, m, H-9), 1.16 (3H, s, H-19), 1.18 (3H,
s, H-18), 1.42 (1H, dd, J = 8.5, 11.8 Hz, H-11), 1.60 (1H, m, H-8b),
1.68 (1H, dd, J = 9.9, 14.8, H-1b), 1.74 (3H, s, H-20), 1.76 (1H, dd,
J = 3.2, 9.4 Hz, H-4), 1.95 (1H, m, H-7a), 1.96 (1H, m, H-8a), 2.07
(1H, m, H-2), 2.23 (1H, br s, H-17a), 2.35 (1H, d, J = 3.4 Hz, H-
17b), 3.15 (1H, dd, J = 9.4, 14.3 Hz, H-1a), 3.60 (2H, d, J = 16.2 Hz,
H-20), 3.72 (2H, d, J = 16.2 Hz, H-200), 5.61 (1H, br s, H-3), 5.77
(1H, d, J = 10.1 Hz, H-5), 6.68 (1H, d, J = 9.4 Hz, H-12), 7.16 (4H,
m, H-40/H-400/H-80/H-800), 7.24 (2H, m, H-60/H-600), 7.36 (4H, m, H-
50/H-500/H-70/H-700); 13C NMR (100 MHz, CDCl3): d 12.2 (C-20),
14.6 (C-16), 16.2 (C-19), 20.1 (C-8), 26.4 (C-10), 29.0 (C-11), 29.4
(C-18), 31.0 (C-7), 33.9 (C-9), 37.4 (C-2), 39.1 (C-20), 40.8 (C-200),
49.7 (C-1), 51.7 (C-4), 55.7 (C-17), 59.0 (C-6), 66.5 (C-5), 82.8 (C-
3), 88.6 (C-15), 128,6 (C-40/C-50/C-7/C-80), 128.9 (C-60), 129.1 (C-
50/C-70), 129.4 (C-400/C-800), 133.6 (C-30), 134.6 (C-300), 136.0 (C-13),
141.1 (C-12), 171.6 (C-100), 175.0 (C-10), 199.2 (C-14).
4.5.6. Preparation of epoxyboetirane I, 3b,5a-di(2-ethylhexanoyl)-
15b-hydroxy-6(17)-epoxylathyr-12E-en-14-one (13)
Compound 13 was obtained from reaction of 6 (30 mg) with
60 ll of 2-ethylhexanoyl chloride (Sigma–Aldrich Chemie GmbH,
Riedstrasse D-89555, Steinheim, Germany). The residue was puri-
ﬁed by CC (n-hexane–CH2Cl2, 1:1–0:1 and CH2Cl2–EtOAc, 9:1)
and prep. TLC (CH2Cl2–EtOAc, 9:1) to give 20 mg (yield 40%) of
an amorphous white solid. ½a25D +234 (c 0.32, CHCl3); IR (KBr) mmax
3442, 3054, 1713, 1653, 1636, 1265 cm1; ESIMSm/z 625 [M+Na]+,
641 [M+K]+; 1H NMR (400 MHz, CDCl3): d 0.86 (3H, d, J = 6.8 Hz, H-
16), 0.89 (6H, m, H-60/-600), 0.94 (6H, t, J = 6.4 Hz, H-4a0/H-4a00), 1.05
(3H, s, H-19), 1.08 (1H, m, H-9), 1.11 (3H, s, H-18), 1.12 (1H, m, H-
11), 1.17 (2H, m, H-20/H-200), 1.18 (3H, s, H-20), 1.30 (8H, m, H-40/H-
400/H-50/H-500), 1.65 (1H, m, H-7a), 1.53 (4H, m, H-3a0/H-3a00), 1.64
(4H, m, H-30/H-300), 1.49 (1H, m, H-7b), 1.73 (1H, m, H-1b), 2.21
(2H, m, H-2/H-8), 2.30 (1H, m, H-4), 2.32 (1H, br s, H-17a), 2.78
(1H, s, H-17b), 3.05 (1H, m, H-1a), 5.05 (1H, br s, H-3), 5.61 (1H,
d, J = 10.7 Hz, H-5), 5.91 (1H, d, J = 10.4 Hz, H-12); 13C NMR
(100 MHz, CDCl3): d 11.8 (C-60/C-600), 13.9 (C-4a0/C-4a00), 14.0 (C-
20), 14.3 (C-16), 16.2 (C-19), 20.0 (C-8), 22.6 (C-3a0/C-3a00), 22.7
C. Vieira et al. / Bioorg. Med. Chem. 22 (2014) 6392–6400 6399(C-50), 23.1 (C-500), 25.2 (C-40), 25.4 (C-10), 25.6 (C-400), 28.6 (C-11),
28.8 (C-18), 29.4 (C-30), 29.5 (C-300), 31.5 (C-7), 34.6 (C-9), 37.7 (C-
2), 46.8 (C-20), 46.9 (C-1), 47.1 (C-200), 47.7 (C-4), 50.7 (C-17), 58.7
(C-6), 66.3 (C-5), 85.0 (C-3), 88.5 (C-15), 136.4 (C-13), 143.2 (C-
12), 174.8 (C-100), 181.0 (C-10), 204.0 (C-14).
4.5.7. Preparation of epoxyboetirane J, 3b,5a,15b-
tributanoyloxy-6(17)-epoxylathyr-12E-en-14-one (14)
Compound 14 was obtained from reaction of 6 (25 mg) with
600 ll of butyric anhydride (Sigma–Aldrich Chemie GmbH, Riedst-
rasse D-89555, Steinheim, Germany). The residue was puriﬁed by
CC (n-hexane–CH2Cl2, 4:1 and CH2Cl2–EtOAc, 9:1) to yield 5.6 mg
(yield 14%) of an amorphous white solid. ½a25D +106 (c 0.17, CHCl3);
IR (KBr) mmax 3055, 1715, 1652, 1645, 1424, 1265, 912 cm1; ESIMS
m/z 583 [M+Na]+, 599 [M+K]+; 1H NMR (400 MHz, CDCl3): d 0.95
(9H, m, H-40/H-400/CH3-4000), 1.06 (1H, m, H-9), 1.09 (3H, s, H-18),
1.11 (2H, m, H-8b/H-7b), 1.17 (3H, s, H-19), 1.22 (3H, d,
J = 6.5 Hz, H-16), 1.24 (1H, m, H-8a), 1.37 (1H, m, H-11), 1.50
(1H, dd, J = 3.4, 11.7 Hz, H-1b), 1.59 (3H, br s, H-30/H-300/H-3000),
1.86 (3H, s, H-20), 2.16 (1H, m, H-7a), 2.23 (3H, t, J = 6.9 Hz, H-20/
H-200/H-2000), 2.28 (1H, m, H-2), 2.29 (1H, m, H-17a), 2.38 (1H, d,
J = 3.4 Hz, H-17b), 2.85 (1H, dd, J = 3.9, 10.7 Hz, H-4), 3.27
(1H, d, J = 9.5, 14.0 Hz, H-1a), 5.55 (1H, br s, H-3), 5.99 (1H, d,
J = 11.0 Hz, H-12), 6.06 (1H, d, J = 9.6 Hz, H-5); 13C NMR
(100 MHz, CDCl3): d 12.5 (C-20), 13.7 (C-40/C-400/C-4000), 15.4 (C-
16), 16.5 (C-19), 18.3 (C-30/C-300/C-3000), 20.6 (C-8), 26.4 (C-10),
28.7 (C-11), 29.0 (C-18), 35.2 (C-9), 36.0 (C-7), 36.1 (C-20/C-200/C-
2000), 37.2 (C-2), 47.5 (C-1), 51.6 (C-4), 55.2 (C-17), 58.9 (C-6), 65.6
(C-5), 84.3 (C-3), 89.2 (C-15), 135.6 (C-13), 142.4 (C-12), 166.7
(C-100), 172.2 (C-10), 173.5 (C-1000), 199.4 (C-14).4.6. Biological assays
4.6.1. Cell cultures
The L5178Y mouse T-lymphoma cells (ECACC Cat. No.
87111908, U.S. FDA, Silver Spring, MD, USA) were transfected with
the pHa MDR1/A. The MDR1-expressing cell line was selected by
culturing the infected cells with 60 ng/ml colchicine to maintain
the expression of the MDR phenotype. L5178Y (parental, PAR)
mouse T-cell lymphoma cells and the human MDR1-transfected
subline (MDR) were cultured in McCoy’s 5A medium supple-
mented with 10% heat-inactivated horse serum, L-glutamine and
antibiotics. The cell lines were incubated in a humidiﬁed atmo-
sphere (5% CO2, 95% air) at 37 C.4.6.2. Antiproliferative assay
The antiproliferative effects of the compounds were tested in a
range of increasing concentrations (0.26–133 lM), using L5178Y
mouse T-lymphoma cell line as experimental model. The cells were
distributed into 96-well ﬂat bottom microtiter plates at a concen-
tration of 1  105/ml with a ﬁnal volume of 100 ll of medium per
well. The different concentrations of each compound were added
into duplicate wells. The plates were incubated at 37 C for 72 h;
at the end of the incubation period, 15 ll of MTT solution (from
a 5 mg/ml stock) was added to each well and incubated for 4 h.
Then, 100 ll of SDS (10%) solution was measured into each well
and the plates were further incubated overnight at 37 C. The cell
growth was determined by measuring the optical density (OD) at
550 nm (ref. 630 nm) with a Dynatech MRX vertical beam ELISA
reader. The percentage of inhibition of cell growth was determined
according to this equation:
100 ODsample  ODmedium control
ODcell control  ODmedium control
 
 100:Values of IC50 are means ± standard error of the mean of 3 indepen-
dent experiments.
4.6.3. Rhodamine-123 accumulation assay
The PAR and MDR mouse lymphoma cells were adjusted to a
density of 2  106/ml, resuspended in serum-free McCoy’s 5A
medium and distributed in 500 ll aliquots. The test compounds
were added at 2, 20, 40 or 80 lM; verapamil (positive control) at
22 lM and DMSO at 2% as solvent control. The samples were
incubated for 10 min at room temp, and then 10 ll (5.2 lM ﬁnal
concentration) of rhodamine-123 were added to the samples,
followed by an incubation of 20 min at 37 C. Finally, the samples
were washed twice, resuspended in 500 ll phosphate-buffered sal-
ine (PBS) and the ﬂuorescence of the cell population was analyzed
with a Partec CyFlow ﬂow cytometer (Partec, Münster, Germany).
The histograms were evaluated regarding the mean ﬂuorescence
intensity, the standard deviation and the peak channel of 20,000
individual cells belonging to the total and the gated populations.
See Supplementary data for a representative example. The ﬂuores-
cence activity ratio (FAR) was calculated on the basis of the mea-
sured ﬂuorescence values (FL-1) of treated/untreated resistant
cell line (MDR) and the sensitive cell line (PAR).
FAR ¼ FL-1 MDRtreated=FL-1 MDRuntreated
FL-1 PARtreated=FL-1 PARuntreated4.6.4. Drug combination assay
The combination studies were designed as suggested in the Cal-
cuSyn software manual,20 using a ﬁxed ratio of the drugs across a
concentration gradient. The dilutions of doxorubicin (14.7–0.1 lM)
were made in a horizontal direction and the dilutions of resistant
modiﬁers (at 2-fold of their IC50 values) vertically in a microtitre
plate to a ﬁnal volume of 200 lL of medium per well. The cells
were distributed into plates at 2  105 cells/mL per well and were
incubated for 48 h under the standard conditions. The cell growth
rate was determined after MTT staining, as previously described.
Drug interactions were evaluated according to Chou using the soft-
ware CalcuSyn, version 2.20–22 Each dose–response curve (individ-
ual agents as well as combinations) was ﬁt to a linear model using
the medium effect equation in order to obtain the medium effect
value (corresponding to the IC50) and slope (m). Goodness-of-ﬁt
was assessed using the linear correlation coefﬁcient r, and only
data from analysis with r > 0.90 were presented. The extent of
interaction between drugs was expressed using the combination
index (CI) for mutually exclusive drugs. CI < 0.1: very strong
synergism; 0.1 < CI < 0.3: strong synergism; 0.3 < CI < 0.9:
synergism; 0.9 < CI < 1.1: nearly additive; 1.10 < CI < 1.45: moder-
ate antagonism.20–22
4.6.5. Determination of ATPase activity
Pgp ATPase activity was determined using the SB-MDR1 PREAD-
EASY™ATPase Kit (SOLVOBiotechnology, Szeged, Hungary) accord-
ing to themanufacturer’s instructions. Brieﬂy, the puriﬁed Sf9 insect
membrane vesicles (4 lg protein/well), expressing high levels of
human MDR1, were incubated in 50 lL ATPase assay buffer, plus
the assayed compounds and 2 mMMgATP for 10 min at 37 C. Com-
pounds 4 and 5 were tested at 2, 10, 50 and 100 lM. Final concen-
tration of DMSO in experiment was 2%. ATPase reaction was
stopped and the inorganic phosphate (Pi) produced was measured
colorimetrically (optical density was read at 630 nm). The amount
of Pi liberated by the transporter is proportional to its activity.
Hence, ATPase activities were determined as the difference of the
measured Pi liberation with and without the presence of 1.2 mM
sodium orthovanadate (vanadate-sensitive ATPase activity). This
6400 C. Vieira et al. / Bioorg. Med. Chem. 22 (2014) 6392–6400ATPase kit includes two different tests: the activation and inhibition
assays. The activation assay detects compounds that were
transported by Pgp and thus stimulate baseline vanadate-sensitive
ATPase activity, such as, verapamil (40 lM) that was used as posi-
tive control. In the inhibition assay, the compounds were incubated
in the presence of verapamil (40 lM), and thus, inhibitors may
reduce the verapamil-stimulated vanadate-sensitive ATPase activ-
ity. In some cases inhibitors may inhibit the baseline transporter
ATPase activity as well, such as cyclosporine A (40 lM), also used
as positive control.Acknowledgments
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